Marta Rubino
Seconda Università degli Studi di Napoli
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marta Rubino.
Pediatrics and Neonatology | 2017
Daniele Masarone; Fabio Valente; Marta Rubino; Rossella Vastarella; Rita Gravino; Alessandra Rea; Maria Giovanna Russo; Giuseppe Pacileo; Giuseppe Limongelli
Pediatric heart failure represents an important cause of morbidity and mortality in childhood. Currently, there are well-established guidelines for the management of heart failure in the adult population, but an equivalent consensus in children is lacking. In the clinical setting, ensuring an accurate diagnosis and defining etiology is essential to optimal treatment. Diuretics and angiotensin-converting enzyme inhibition are the first-line therapies, whereas beta-blockers and devices for electric therapy are less used in children than in adults. In the end-stage disease, heart transplantation is the best choice of treatment, while a left ventricular assist device can be used as a bridge to transplantation (due to the difficulties in finding organ donors), recovery (in the case of myocarditis), or destination therapy (for patients with systemic disease).
Heart Failure Clinics | 2016
Giuseppe Limongelli; Daniele Masarone; Valeria Maddaloni; Marta Rubino; Fiorella Fratta; Annapaola Cirillo; Spinelli Barrile Ludovica; Roberta Pacileo; Adelaide Fusco; Guido Coppola; Francesca Pisacane; Eduardo Bossone; Paolo Calabrò; Raffaele Calabrò; Maria Giovanna Russo; Giuseppe Pacileo
Takotsubo syndrome (TTS) is an enigmatic disease with a multifactorial and still unresolved pathogenesis. A genetic predisposition has been suggested based on the few familial TTS cases. Conflicting results have been published regarding the role of functional polymorphisms in relevant candidate genes, such as α1-, β1-, and β2-adrenergic receptors; G protein-coupled receptor kinase 5; and estrogen receptors. Further research is required to help clarify the role of genetic susceptibility in TTS.
Journal of Cardiovascular Development and Disease | 2017
Daniele Masarone; Giuseppe Limongelli; Marta Rubino; Fabio Valente; Rossella Vastarella; Ernesto Ammendola; Rita Gravino; Marina Verrengia; Gemma Salerno; Giuseppe Pacileo
Heart failure patients are predisposed to develop arrhythmias. Supraventricular arrhythmias can exacerbate the heart failure symptoms by decreasing the effective cardiac output and their control require pharmacological, electrical, or catheter-based intervention. In the setting of atrial flutter or atrial fibrillation, anticoagulation becomes paramount to prevent systemic or cerebral embolism. Patients with heart failure are also prone to develop ventricular arrhythmias that can present a challenge to the managing clinician. The management strategy depends on the type of arrhythmia, the underlying structural heart disease, the severity of heart failure, and the range from optimization of heart failure therapy to catheter ablation. Patients with heart failure, irrespective of ejection fraction are at high risk for developing sudden cardiac death, however risk stratification is a clinical challenge and requires a multiparametric evaluation for identification of patients who should undergo implantation of a cardioverter defibrillator. Finally, patients with heart failure can also develop symptomatic bradycardia, caused by sinus node dysfunction or atrio-ventricular block. The treatment of bradycardia in these patients with pacing is usually straightforward but needs some specific issue.
Future Cardiology | 2017
Enrica Golia; Rita Gravino; Alessandra Rea; Daniele Masarone; Marta Rubino; Annapaola Cirillo; Roberta Pacileo; Fiorella Fratta; Maria Giovanna Russo; Giuseppe Pacileo; Giuseppe Limongelli
Pregnancy exposes women with inherited cardiomyopathies to increased risk for arrhythmias and heart failure. In asymptomatic patients with inherited cardiomyopathies, pregnancy is generally well tolerated. Preconception evaluation, risk assessment and proper counseling by a team of experienced physicians are mandatory in managing women with inherited cardiomyopathies planning pregnancy. In this paper, we reviewed the clinical course, risk assessment and management during pregnancy of women with cardiomyopathies.
Journal of Cardiovascular Echography | 2018
Giuseppe Limongelli; Daniele Masarone; Marina Verrengia; Rita Gravino; Gemma Salerno; Silvia Castelletti; Marta Rubino; Tommaso Marrazzo; Antonio Pisani; Franco Cecchi; Perry M. Elliott; Giuseppe Pacileo
Hypertrophic cardiomyopathy (HCM) is the most common known inherited heart disorder, with a prevalence of 1:500 of the adult population. Etiology of HCM can be heterogeneous, with sarcomeric gene disease as the leading cause in up to 60% of the patients, and with a number of possible different diseases (phenocopies) in about 10%–15% of the patients. Early diagnosis of storage and infiltrative disorders, particularly those with specific treatments (i.e., Fabry disease and/or amyloidosis), means early management and treatment, with a significant impact on patients prognosis. Here, we report on four different cases of HCM, highlighting difficulties to make differential diagnosis of different forms of cardiomyopathies, and their potential impact on the management.
Archive | 2017
Daniele Masarone; Ernesto Ammendola; Anna Rago; Rita Gravino; Gemma Salerno; Marta Rubino; Tommaso Marrazzo; Antonio Molino; Paolo Calabrò; Giuseppe Pacileo; Giuseppe Limongelli
Patients with heart failure (HF) may develop a range of bradyarrhythmias including sinus node dysfunction, various degrees of atrioventricular block, and ventricular conduction delay. Device implantation has been recommended in these patients, but the specific etiology should be sought as it may influence the choice of the type of device required (pacemaker vs. implantable cardiac defibrillator). Also, pacing mode must be carefully set in patients with heart failure (HF) and left ventricular systolic dysfunction.In this chapter, we summarize the knowledge required for a tailored approach to bradyarrhythmias in patients with heart failure.
Giornale italiano di cardiologia | 2017
Pierluigi Russo; Generoso Andria; Alessandra Baldinelli; Maria Lucia Boffi; Emma Cerini; Roberto Della Casa; Andrea Imperatori; Giovanni Battista Luciani; Elisa Morra; Rossella Parini; Maurizio Pieroni; Maria Antonia Prioli; Luca Ragni; Claudio Rapezzi; Gabriele Rinelli; Marta Rubino; Cristiano Sarais; Pietro Sciacca; Francesco Seddio; Giuseppe Limongelli
Mucopolysaccharidoses (MPS) represent a group of rare lysosomal storage disorders, with a heterogeneous clinical presentation in terms of inheritance (autosomal and X-linked recessive), age of onset (infants, children, and adults), systemic and cardiac manifestations (mild to severe disease forms). Evidence-based recommendations on the diagnosis and management of cardiovascular disease in MPS are scarce. GICEM (Gruppo Italiano Cardiologi Esperti Malattie Metaboliche) is a group of cardiologists, cardiac surgeons and pediatricians with a specific expertise in metabolic diseases including MPS. In this paper, we report our experience and recommendations on the diagnosis and management of cardiovascular aspects in MPS, with a tailored approach based on current evidence, and taking into account MPS phenotype (particularly, I, II, IVa, VI), age at presentation, and severity of systemic and cardiac manifestations.
Future Cardiology | 2017
Daniele Masarone; Giovanni Duro; Santo Dellegrottaglie; Paolo Colomba; Marta Rubino; Annapaola Cirillo; Antonio Pisani; Martina Caiazza; Perry M. Elliott; Paolo Calabrò; Giuseppe Pacileo; Giuseppe Limongelli
AIM Anderson-Fabry disease (AFD) is a hereditary disorder caused by a deficiency in the lysosomal enzyme α-galactosidase A which causes dysfunctions in multiple organ systems. Cardiac manifestation includes left ventricular hypertrophy, thickening of the valves, conduction disturbances and in the late phase, extensive areas of myocardial fibrosis with increased risk of sudden cardiac death. Case example: A case of AFD with exclusive cardiac involvement is described. During follow-up, due to the high risk of life-threatening arrhythmic events, implantation of an implantable cardioverter defibrillator is performed. CONCLUSION AFD patients with advanced cardiac disease might represent a subgroup of patients who may require an implantable cardioverter defibrillator for primary prevention of sudden cardiac death.
Archive | 2018
Daniele Masarone; Ernesto Ammendola; Anna Rago; Rita Gravino; Gemma Salerno; Marta Rubino; Tommaso Marrazzo; Antonio Molino; Paolo Calabrò; Giuseppe Pacileo; Giuseppe Limongelli
Current Opinion in Obstetrics & Gynecology | 2018
Giuseppe Limongelli; Marta Rubino; Augusto Esposito; M. G. Russo; Giuseppe Pacileo